Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Contribution of Neutrophils to Acute Lung Injury
2010
Interactions of thrombospondin with endothelial cells: receptor-mediated binding and degradation.
1987
Mechanisms of Thrombus Formation
2008 Standout
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
Prevention of Deep Vein Thrombosis after Elective Hip Surgery
1991
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
Multiple Biomarkers for the Prediction of First Major Cardiovascular Events and Death
2006 Standout
A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis
1998 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Subcutaneous Heparin Compared with Continuous Intravenous Heparin Administration in the Initial Treatment of Deep Vein Thrombosis
1992
Taking advantage of luminescent lanthanide ions
2005 Standout
The Acute Respiratory Distress Syndrome
2000 Standout
Plasma levels of the three endothelial-specific proteins von Willebrand factor, tissue factor pathway inhibitor, and thrombomodulin do not predict the development of acute respiratory distress syndrome
1999
Childhood obesity: public-health crisis, common sense cure
2002 Standout
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
1995 Standout
Fibrinolytic Activation Markers Predict Myocardial Infarction in the Elderly
1999
Smoking, hemorheologic factors, and progression of peripheral arterial disease in patients with claudication
1998
Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice
2017 Standout
Activation of polymorphonuclear leukocytes in oleic acid-induced lung injury
1998
Mutation in the Gene Coding for Coagulation Factor V and the Risk of Myocardial Infarction, Stroke, and Venous Thrombosis in Apparently Healthy Men
1995 Standout
The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis
1990
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Platelet Activation and Atherothrombosis
2007 Standout
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
1993 Standout
Importance of the Hinge Region between α-Helix F and the Main Part of Serpins, Based upon Identification of the Epitope of Plasminogen Activator Inhibitor Type 1 Neutralizing Antibodies
2000
The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischaemia
1996
The Clinical Course of Pulmonary Embolism
1992 Standout
A Prospective Study of Venous Thromboembolism after Major Trauma
1994 Standout
Pulmonary endothelium in acute lung injury: from basic science to the critically ill
2004
The potential role of platelet microparticles in atherosclerosis
2005
Antithrombotic Therapy for Venous Thromboembolic Disease
1989
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
2004 Standout
The pathogenic basis of malaria
2002 StandoutNature
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Heparin and Low-Molecular-Weight Heparin
1998
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
2003 Standout
Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin
1995 Standout
Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication
2006
Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome
1997
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
Disseminated Intravascular Coagulation
1999 Standout
Heparin
1991
Acute effects of cigarette smoke on inflammation and oxidative stress: a review
2004
Antithrombotic Therapy for Venous Thromboembolic Disease
2001 Standout
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
1997 Standout
Hemorrhagic Complications of Anticoagulant Treatment
1998
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
1994
A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients
1999 Standout
Hemorrhagic Complications of Anticoagulant Treatment
2001 Standout
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
Vascular Immunotargeting of Glucose Oxidase to the Endothelial Antigens Induces Distinct Forms of Oxidant Acute Lung Injury
2002
Pathogenesis of indirect (secondary) acute lung injury
2011
Pharmacotherapeutic Aspects of Unfractionated and Low Molecular Weight Heparins
1990
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Hemorrhagic Complications of Anticoagulant Treatment
2004
The Tumor Necrosis Factor Ligand and Receptor Families
1996 StandoutNobel
A Novel Alveolar Type I Cell–Specific Biochemical Marker of Human Acute Lung Injury
2000
Extracellular DNA traps promote thrombosis
2010 Standout
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
1991
Optimal Therapeutic Level of Heparin Therapy in Patients With Venous Thrombosis
1992
Extracellular vesicles: Exosomes, microvesicles, and friends
2013 Standout
The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits
1982
Diurnal Rhythm in Anticoagulant Effect of Heparin during a Low Dose Constant Rate Infusion
1992
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
1989
Administration of C1 Inhibitor Reduces Neutrophil Activation in Patients with Sepsis
2003
Serpin Structure, Mechanism, and Function
2002 Standout
Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin
1981
C-Reactive Protein, Fibrin D-Dimer, and Incident Ischemic Heart Disease in the Speedwell Study
2001
A new low molecular weight heparin derivative. In vitro and in vivo studies
1983
Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
1995
Risk of complications during intravenous heparin therapy.
1982
Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage
2006
Plasminogen Activators, Tissue Degradation, and Cancer
1985 Standout
Time-Resolution in Fluorometry Technologies, Labels, and Applications in Bioanalytical Assays
2001
Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later
2016
Quantitative and qualitative progression of peripheral arterial disease by non-invasive testing
1999
Binding and endocytosis of heparin by human endothelial cells in culture
1985
Subcutaneous administration of heparin a randomised comparison with intravenous administration of heparin to patients with deep-vein thrombosis
1982
Neutralization of heparin by histone and its subfractions
1983
von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects
1999
Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
1984
Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.
1994
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
1996
Biological implications of a 3 å structure of dimeric antithrombin
1994
Effect of Heparin and Heparin Fractions on Platelet Aggregation
1980
Warfarin
1984
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration.
1994
Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative study
1985
The structural and functional properties of thrombospondin
1986
Two Daily Subcutaneous Injections of Fragmin as Compared with Intravenous Standard Heparin in the Treatment of Deep Venous Thrombosis (DVT)
1990
Hemorrhagic Complications of Anticoagulant Treatment
1992
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
1990
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
2018 StandoutScience
Epidemiology of Peripheral Artery Disease
2015 Standout
Endocytosis of urokinase-plasminogen activator inhibitor type 1 complexes bound to a chimeric transmembrane urokinase receptor.
1994 StandoutNobel
Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo
1982
Coronary Plaque Disruption
1995 Standout
The Effects of Standard and Low Molecular Weight Heparin on Bone Nodule Formation In Vitro
1998
Adjusted Subcutaneous Heparin or Continuous Intravenous Heparin in Patients with Acute Deep Vein Thrombosis
1987
Low-Molecular-Weight Heparins
1997 Standout
Disseminated intravascular coagulation due to malignancy.
1990
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
1993 Standout
Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomised trial.
1987
Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men.
1994
Management of Deep Vein Thrombosis and Pulmonary Embolism
1996
Low-affinity heparin stimulates the inactivation of plasminogen activator inhibitor-1 by thrombin
1994
Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration
1985
The Acute Respiratory Distress Syndrome
1996 Standout
Hemorrhagic Complications of Anticoagulant Treatment
1995
Treatment of Venous Thromboembolism
1999
Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis
1986
Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
2020 Standout
Clinical relevance of distal deep vein thrombosis. Review of literature data.
2006
Tumors: Wounds That Do Not Heal
1986 Standout
Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
1984
The Use of Soluble Fibrin in Evaluating the Acute and Chronic Hypercoagulable State
1999
Thrombospondin stimulates motility of human neutrophils.
1990 StandoutNobel
Fat distribution and hemostatic measures in obese children
1998
Deep Venous Thrombosis and Pulmonary Embolism in Trauma Patients
1988
Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma
1990
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers
1986
Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma
1979
Works of Ian MacGregor being referenced
Application of a Time–Resolved Fluoroimmunoassay for the Analysis of Normal Prion Protein in Human Blood and Its Components
1999
Plasminogen activator inhibitor (PAI‐1) in plasma and platelets
1988
Reduction of the Proteolytic Activity of Neutrophils by Exposure to Cigarette Smoke in Vitro
1991
The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease
1994
The release of prion protein from platelets during storage of apheresis platelets
2001
Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease
1993
Plasma elastase levels and the development of the adult respiratory distress syndrome.
1995
Modulation of human endothelial thrombomodulin by neutrophils and their release products.
1997
Measurement of soluble fibrin in a variety of animal species
1989
Tissue plasminogen activator in human plasma measured by radioimmunoassay
1983
Quantitation by Radioimmunoassay of Thrombospondin Synthesised and Secreted by Human Endothelial Cells
1984
Heparin receptors on mouse macrophages
1983
An objective study of alternative methods of heparin administration
1980
A Comparative Study Using Immunological and Biological Assays of the Haemostatic Responses to DDAVP Infusion Venous Occlusion and Exercise in Normal Men
1984
Inhibition of human factor Xa by various plasma protease inhibitors
1982
Anticoagulant activities of four unfractionated and fractionated heparins
1978
The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components
2006
Characterisation of Epitopes on Human Tissue Plasminogen Activator Recognised by a Group of Monoclonal Antibodies
1985
The anti-heparin properties of human low-density lipoprotein
1980
Application of a Time‐Resolved Fluoroimmunoassay for the Analysis of Normal Prion Protein in Human Blood and Its Components
1999
Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis
1993
Tandem purification of mouse IgM monoclonal atibodies produced in vitro using anion-exchange and gel fast protein liquid chromatography
1986
An Enzyme-Linked Immunosorbent Assay (ELISA) Used to Study the Cellular Secretion of Endothelial Plasminogen Activator Inhibitor (PAI-1)
1988
Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III
1979
Molecular weight dependence of the anticoagulant properties of heparin: Intravenous and subcutaneous administration of fractionated heparins to man
1979